MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC

Trial Details

NCT ID
NCT05286957
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • adjuvant tislelizumab and chemotherapy for MRD+ patients
  • adjuvant chemotherapy for MRD- patients
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Patient with age ≥ 18 years old, gender is not limited.
  • Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB.
  • Receiving complete resection
  • Paraffin-embedded sections (10-15 pieces) or fresh frozen tissue are required.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →